Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Alan Venook, MD

    TitleProfessor
    SchoolUCSF School of Medicine
    DepartmentMedicine
    Address1600 Divisadero St.,MZ Bldg D
    San Francisco CA 94143
    Phone415-353-2745

       ORNG Applications 
       Websites
       Global Health
       More Info

       Bibliographic 
       Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Nixon AB, Pang H, Starr MD, Friedman PN, Bertagnolli MM, Kindler HL, Goldberg RM, Venook AP, Hurwitz HI. Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance). Clin Cancer Res. 2013 Dec 15; 19(24):6957-66.
        View in: PubMed
      2. Jeon J, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Wigler DS, Atienza D, Messino M, Kindler H, Venook A, Fuchs CS, Meyerhardt JA. Impact of Physical Activity After Cancer Diagnosis on Survival in Patients With Recurrent Colon Cancer: Findings From CALGB 89803/Alliance. Clin Colorectal Cancer. 2013 Dec; 12(4):233-8.
        View in: PubMed
      3. Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br J Cancer. 2013 Oct 1; 109(7):1725-34.
        View in: PubMed
      4. Van Loon K, Venook AP. Biomarkers in colon cancer: the chasm between expectations and reality. Oncology (Williston Park). 2013 Aug; 27(8):758, 763.
        View in: PubMed
      5. Abou-Alfa GK, Venook AP. The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached? Lancet Oncol. 2013 Jun; 14(7):e283-8.
        View in: PubMed
      6. Benson AB, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W, Sofocleous CT, Venook AP, Willett CG, Gregory KM, Freedman-Cass DA. Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013 May 1; 11(5):519-28.
        View in: PubMed
      7. Maru D, Venook AP, Ellis LM. Predictive biomarkers for bevacizumab: are we there yet? Clin Cancer Res. 2013 Jun 1; 19(11):2824-7.
        View in: PubMed
      8. Venook AP, Niedzwiecki D, Lopatin M, Ye X, Lee M, Friedman PN, Frankel W, Clark-Langone K, Millward C, Shak S, Goldberg RM, Mahmoud NN, Warren RS, Schilsky RL, Bertagnolli MM. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. J Clin Oncol. 2013 May 10; 31(14):1775-81.
        View in: PubMed
      9. Kelley RK, Nimeiri HS, Munster PN, Vergo MT, Huang Y, Li CM, Hwang J, Mulcahy MF, Yeh BM, Kuhn P, Luttgen MS, Grabowsky JA, Stucky-Marshall L, Korn WM, Ko AH, Bergsland EK, Benson AB, Venook AP. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates. Ann Oncol. 2013 Jul; 24(7):1900-7.
        View in: PubMed
      10. Katz MH, Marsh R, Herman JM, Shi Q, Collison E, Venook AP, Kindler HL, Alberts SR, Philip P, Lowy AM, Pisters PW, Posner MC, Berlin JD, Ahmad SA. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 2013 Aug; 20(8):2787-95.
        View in: PubMed
      11. Benson AB, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W, Sofocleous CT, Venook AP, Willett CG, Gregory KM, Freedman-Cass DA. Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013 Feb 1; 11(2):141-52; quiz 152.
        View in: PubMed
      12. Van Loon K, Wigler D, Niedzwiecki D, Venook AP, Fuchs C, Blanke C, Saltz L, Goldberg RM, Meyerhardt JA. Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients: findings from CALGB 89803 and CALGB 80405. Clin Colorectal Cancer. 2013 Jun; 12(2):95-102.
        View in: PubMed
      13. Ang CS, Kelley RK, Choti MA, Cosgrove DP, Chou JF, Klimstra D, Torbenson MS, Ferrell L, Pawlik TM, Fong Y, O'Reilly EM, Ma J, McGuire J, Vallarapu GP, Griffin A, Stipa F, Capanu M, Dematteo RP, Venook AP, Abou-Alfa GK. Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium. Gastrointest Cancer Res. 2013 Jan; 6(1):3-9.
        View in: PubMed
      14. Benson AB, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fuchs CS, Grem JL, Hunt S, Leong LA, Lin E, Martin MG, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W, Sofocleous CT, Venook AP, Willett CG, Freedman-Cass DA, Gregory KM. Rectal cancer. J Natl Compr Canc Netw. 2012 Dec 1; 10(12):1528-64.
        View in: PubMed
      15. Meyerhardt JA, Sato K, Niedzwiecki D, Ye C, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Wigler DS, Venook A, Fuchs CS. Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Natl Cancer Inst. 2012 Nov 21; 104(22):1702-11.
        View in: PubMed
      16. Van Loon K, Venook AP. Counterpoint: Adjuvant therapy in stage II colon cancer: pain not justified by the gain. J Natl Compr Canc Netw. 2012 Nov 1; 10(11):1379-86.
        View in: PubMed
      17. Ko AH, Espinoza AM, Jones KA, Venook AP, Bergsland EK, Kelley RK, Dito E, Ong A, Hanover CS, Coakley FV, Tempero MA. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. Am J Clin Oncol. 2012 Oct; 35(5):411-7.
        View in: PubMed
      18. Oxnard GR, Morris MJ, Hodi FS, Baker LH, Kris MG, Venook AP, Schwartz LH. When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J Natl Cancer Inst. 2012 Oct 17; 104(20):1534-41.
        View in: PubMed
      19. Parekh JR, Wang SC, Bergsland EK, Venook AP, Warren RS, Kim GE, Nakakura EK. Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients. Pancreas. 2012 Aug; 41(6):840-4.
        View in: PubMed
      20. Kelley RK, Hirose R, Venook AP. Can we cure cholangiocarcinoma with neoadjuvant chemoradiation and liver transplantation? Time for a multicenter trial. Liver Transpl. 2012 May; 18(5):509-13.
        View in: PubMed
      21. Benson AB, Arnoletti JP, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Engstrom PF, Enzinger PC, Fakih MG, Fleshman JW, Fuchs CS, Grem JL, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W, Sofocleous CT, Venook AP, Willett C, Freedman-Cass DA. Anal Carcinoma, Version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012 Apr; 10(4):449-54.
        View in: PubMed
      22. Kelley RK, Atreya C, Venook AP, Febbo PG. Predictive biomarkers in advance of a companion drug: ahead of their time? J Natl Compr Canc Netw. 2012 Mar; 10(3):303-9.
        View in: PubMed
      23. Van Loon K, Venook AP. Metastatic colorectal cancer: a curable disease. Oncology (Williston Park). 2012 Mar; 26(3):275-6, 282.
        View in: PubMed
      24. Janne d'Othée B, Sofocleous CT, Hanna N, Lewandowski RJ, Soulen MC, Vauthey JN, Cohen SJ, Venook AP, Johnson MS, Kennedy AS, Murthy R, Geschwind JF, Kee ST. Development of a research agenda for the management of metastatic colorectal cancer: proceedings from a multidisciplinary research consensus panel. J Vasc Interv Radiol. 2012 Feb; 23(2):153-63.
        View in: PubMed
      25. Benson AB, Arnoletti JP, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Engstrom PF, Enzinger PC, Fleshman JW, Fuchs CS, Grem JL, Knol JA, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W, Sofocleous CT, Venook AP, Willett C. Colon cancer. J Natl Compr Canc Netw. 2011 Nov; 9(11):1238-90.
        View in: PubMed
      26. Kelley RK, Wang G, Venook AP. Biomarker use in colorectal cancer therapy. J Natl Compr Canc Netw. 2011 Nov; 9(11):1293-302.
        View in: PubMed
      27. Ng K, Ogino S, Meyerhardt JA, Chan JA, Chan AT, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Benson AB, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Bertagnolli MM, Venook AP, Fuchs CS. Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. J Natl Cancer Inst. 2011 Oct 19; 103(20):1540-51.
        View in: PubMed
      28. Van Loon K, Venook AP. Adjuvant treatment of colon cancer: what is next? Curr Opin Oncol. 2011 Jul; 23(4):403-9.
        View in: PubMed
      29. Roberts AS, Campa MJ, Gottlin EB, Jiang C, Owzar K, Kindler HL, Venook AP, Goldberg RM, O'Reilly EM, Patz EF. Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303). Cancer. 2012 Jan 15; 118(2):571-8.
        View in: PubMed
      30. Espinoza AM, Venook AP. Lactic acidosis and colon cancer: oncologic emergency? Clin Colorectal Cancer. 2011 Sep; 10(3):194-7.
        View in: PubMed
      31. Kelley RK, Venook AP. Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling? Clin Colorectal Cancer. 2011 Jun; 10(2):73-80.
        View in: PubMed
      32. Peng J, Chen W, Venook AP, Sheng W, Xu Y, Guan Z, Cai G, Cai S. Long-term outcome of early-stage rectal cancer undergoing standard resection and local excision. Clin Colorectal Cancer. 2011 Mar 1; 10(1):37-41.
        View in: PubMed
      33. Gordan JD, Chay WY, Kelley RK, Ko AH, Choo SP, Venook AP. "And what other medications are you taking?". J Clin Oncol. 2011 Apr 10; 29(11):e288-91.
        View in: PubMed
      34. Kelley RK, Van Bebber SL, Phillips KA, Venook AP. Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer. J Natl Compr Canc Netw. 2011 Jan; 9(1):13-25.
        View in: PubMed
      35. Peng J, Sheng W, Huang D, Venook AP, Xu Y, Guan Z, Cai S. Perineural invasion in pT3N0 rectal cancer: the incidence and its prognostic effect. Cancer. 2011 Apr 1; 117(7):1415-21.
        View in: PubMed
      36. Kelley RK, Venook AP. Nonadherence to imatinib during an economic downturn. N Engl J Med. 2010 Aug 5; 363(6):596-8.
        View in: PubMed
      37. Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, Gores G, Kerlan R, Merle P, O'Neil B, Poon R, Schwartz L, Tepper J, Yao F, Haller D, Mooney M, Venook A. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2010 Sep 1; 28(25):3994-4005.
        View in: PubMed
      38. Roberts JP, Venook A, Kerlan R, Yao F. Hepatocellular carcinoma: Ablate and wait versus rapid transplantation. Liver Transpl. 2010 Aug; 16(8):925-9.
        View in: PubMed
      39. Lencioni R, Marrero J, Venook A, Ye SL, Kudo M. Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study. Int J Clin Pract. 2010 Jul; 64(8):1034-41.
        View in: PubMed
      40. Schwarz RE, Abou-Alfa GK, Geschwind JF, Krishnan S, Salem R, Venook AP. Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. HPB (Oxford). 2010 Jun; 12(5):313-20.
        View in: PubMed
      41. Chung KY, Gore I, Fong L, Venook A, Beck SB, Dorazio P, Criscitiello PJ, Healey DI, Huang B, Gomez-Navarro J, Saltz LB. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J Clin Oncol. 2010 Jul 20; 28(21):3485-90.
        View in: PubMed
      42. Wang SC, Parekh JR, Zuraek MB, Venook AP, Bergsland EK, Warren RS, Nakakura EK. Identification of unknown primary tumors in patients with neuroendocrine liver metastases. Arch Surg. 2010 Mar; 145(3):276-80.
        View in: PubMed
      43. Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1051-7.
        View in: PubMed
      44. Engstrom PF, Arnoletti JP, Benson AB, Berlin JD, Berry JM, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J, Fuchs C, Grem JL, Knol JA, Leong LA, Lin E, Mulcahy MF, Rohren E, Ryan DP, Saltz L, Shibata D, Skibber JM, Small W, Sofocleous C, Thomas J, Venook AP, Willett C. NCCN clinical practice guidelines in oncology. Anal carcinoma. J Natl Compr Canc Netw. 2010 Jan; 8(1):106-20.
        View in: PubMed
      45. Lencioni R, Chen XP, Dagher L, Venook AP. Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved? Oncologist. 2010; 15 Suppl 4:42-52.
        View in: PubMed
      46. Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist. 2010; 15 Suppl 4:5-13.
        View in: PubMed
      47. Engstrom PF, Arnoletti JP, Benson AB, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C. NCCN Clinical Practice Guidelines in Oncology: rectal cancer. J Natl Compr Canc Netw. 2009 Sep; 7(8):838-81.
        View in: PubMed
      48. Engstrom PF, Arnoletti JP, Benson AB, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C. NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw. 2009 Sep; 7(8):778-831.
        View in: PubMed
      49. Kelley R, Venook AP. Drug development in advanced colorectal cancer: challenges and opportunities. Curr Oncol Rep. 2009 May; 11(3):175-85.
        View in: PubMed
      50. Benson AB, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, Covey A, Curley SA, D'Angelica MI, Davila R, Ensminger WD, Gibbs JF, Laheru D, Malafa MP, Marrero J, Meranze SG, Mulvihill SJ, Park JO, Posey JA, Sachdev J, Salem R, Sigurdson ER, Sofocleous C, Vauthey JN, Venook AP, Goff LW, Yen Y, Zhu AX. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw. 2009 Apr; 7(4):350-91.
        View in: PubMed
      51. Shah U, O'Neil B, Allen J, Goldberg RM, Bernard S, Moore D, Venook AP, Morse MM. A Phase II Study of Long-Acting Octreotide in Patients With Advanced Hepatocellular Carcinoma and CLIP Score of 3 or Higher. Gastrointest Cancer Res. 2009 Mar; 3(2):45-8.
        View in: PubMed
      52. Fan SK, Venook AP, Lu Y. Design issues in dose-finding Phase I trials for combinations of two agents. J Biopharm Stat. 2009; 19(3):509-23.
        View in: PubMed
      53. Kelley RK, Venook AP. Sorafenib in hepatocellular carcinoma: separating the hype from the hope. J Clin Oncol. 2008 Dec 20; 26(36):5845-8.
        View in: PubMed
      54. Wong D, Ko AH, Hwang J, Venook AP, Bergsland EK, Tempero MA. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas. 2008 Oct; 37(3):269-74.
        View in: PubMed
      55. Sterling RK, Jeffers L, Gordon F, Venook AP, Reddy KR, Satomura S, Kanke F, Schwartz ME, Sherman M. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2009 Jan; 7(1):104-13.
        View in: PubMed
      56. Figlin RA, Brown E, Armstrong AJ, Akerley W, Benson AB, Burstein HJ, Ettinger DS, Febbo PG, Fury MG, Hudes GR, Kies MS, Kwak EL, Morgan RJ, Mortimer J, Reckamp K, Venook AP, Worden F, Yen Y. NCCN Task Force Report: mTOR inhibition in solid tumors. J Natl Compr Canc Netw. 2008 Sep; 6 Suppl 5:S1-20; quiz S21-2.
        View in: PubMed
      57. Abou-Alfa GK, Venook AP. The impact of new data in the treatment of advanced hepatocellular carcinoma. Curr Oncol Rep. 2008 May; 10(3):199-205.
        View in: PubMed
      58. Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs. 2008 Oct; 26(5):463-71.
        View in: PubMed
      59. Choo SP, Venook AP. Responding to the rising incidence of hepatocellular carcinoma with targeted therapy. Gastrointest Cancer Res. 2008 Mar; 2(2):96-7.
        View in: PubMed
      60. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study. Cancer Invest. 2008 Feb; 26(1):47-52.
        View in: PubMed
      61. Berlin JD, Venook A, Bergsland E, Rothenberg M, Lockhart AC, Rosen L. Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma. Clin Colorectal Cancer. 2008 Jan; 7(1):44-7.
        View in: PubMed
      62. O'Neil BH, Venook AP. Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy. Oncologist. 2007 Dec; 12(12):1425-32.
        View in: PubMed
      63. Posner MC, Niedzwiecki D, Venook AP, Hollis DR, Kindler HL, Martin EW, Schilsky RL, Goldberg RM, Mayer RJ. A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903. Ann Surg Oncol. 2008 Jan; 15(1):158-64.
        View in: PubMed
      64. Goldberg RM, Marshall JL, Kachnic LA, Venook AP. Section I: essentials of ensuring excellence in cancer care. Gastrointest Cancer Res. 2007 Nov; 1(6 Suppl):S1-3.
        View in: PubMed
      65. Hochster HS, O'Reilly EM, Ajani JA, Venook AP. Section III: Treatment of Advanced Gastrointestinal Cancers. Gastrointest Cancer Res. 2007 Nov; 1(6 Suppl):S8-S12.
        View in: PubMed
      66. Goldberg RM, Marshall JL, Ajani JA, Philip PA, O'Reilly EM, Venook AP. Section IV: Significance of Recent Study Results and Future Research Directions in Gastrointestinal Oncology. Gastrointest Cancer Res. 2007 Nov; 1(6 Suppl):S13-6.
        View in: PubMed
      67. Engstrom PF, Arnoletti JP, Benson AB, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Early DS, Fakih MG, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW, Rao S, Saltz L, Shibata D, Skibber JM, Venook AP. Colon cancer. J Natl Compr Canc Netw. 2007 Oct; 5(9):884-925.
        View in: PubMed
      68. Kavanagh B, Ko A, Venook A, Margolin K, Zeh H, Lotze M, Schillinger B, Liu W, Lu Y, Mitsky P, Schilling M, Bercovici N, Loudovaris M, Guillermo R, Lee SM, Bender J, Mills B, Fong L. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J Immunother. 2007 Oct; 30(7):762-72.
        View in: PubMed
      69. Engstrom PF, Arnoletti JP, Benson AB, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Early DS, Fakih MG, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW, Rao S, Saltz L, Shibata D, Skibber JM, Venook AP. Rectal cancer. J Natl Compr Canc Netw. 2007 Oct; 5(9):940-81.
        View in: PubMed
      70. Choo SP, Venook AP. An alternative therapy for patients with hepatic impairment? Onkologie. 2007 Oct; 30(10):474-5.
        View in: PubMed
      71. Hecht JR, Patnaik A, Berlin J, Venook A, Malik I, Tchekmedyian S, Navale L, Amado RG, Meropol NJ. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer. 2007 Sep 1; 110(5):980-8.
        View in: PubMed
      72. Allegra C, Blanke C, Buyse M, Goldberg R, Grothey A, Meropol NJ, Saltz L, Venook A, Yothers G, Sargent D. End points in advanced colon cancer clinical trials: a review and proposal. J Clin Oncol. 2007 Aug 20; 25(24):3572-5.
        View in: PubMed
      73. Sterling RK, Jeffers L, Gordon F, Sherman M, Venook AP, Reddy KR, Satomura S, Schwartz ME. Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am J Gastroenterol. 2007 Oct; 102(10):2196-205.
        View in: PubMed
      74. Nakakura EK, Venook AP, Bergsland EK. Systemic and regional nonsurgical therapy--what is the optimal strategy for metastatic neuroendocrine cancer? Surg Oncol Clin N Am. 2007 Jul; 16(3):639-51, x.
        View in: PubMed
      75. Venook AP, Blanke CD, Niedzwiecki D, Lenz HJ, Taylor JR, Hollis DR, Sutherland S, Goldberg RM. Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 Trial: a phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinoma. Clin Colorectal Cancer. 2007 May; 6(7):536-8.
        View in: PubMed
      76. Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2007 Jul 1; 68(3):809-16.
        View in: PubMed
      77. Qayyum A, Lee GK, Yeh BM, Allen JN, Venook AP, Coakley FV. Frequency of hepatic contour abnormalities and signs of portal hypertension at CT in patients receiving chemotherapy for breast cancer metastatic to the liver. Clin Imaging. 2007 Jan-Feb; 31(1):6-10.
        View in: PubMed
      78. Bartlett DL, Berlin J, Lauwers GY, Messersmith WA, Petrelli NJ, Venook AP. Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006 Oct; 13(10):1284-92.
        View in: PubMed
      79. Benson AB, Bekaii-Saab T, Ben-Josef E, Blumgart L, Clary BM, Curley SA, Davila R, Earle CC, Ensminger WD, Gibbs JF, Laheru D, Langnas AN, Mulvihill SJ, Nemcek AA, Posey JA, Sigurdson ER, Sinanan M, Vauthey JN, Venook AP, Wagman LD, Yeatman TJ. Hepatobiliary cancers. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Sep; 4(8):728-50.
        View in: PubMed
      80. Kulke MH, Bergsland EK, Ryan DP, Enzinger PC, Lynch TJ, Zhu AX, Meyerhardt JA, Heymach JV, Fogler WE, Sidor C, Michelini A, Kinsella K, Venook AP, Fuchs CS. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol. 2006 Aug 1; 24(22):3555-61.
        View in: PubMed
      81. Ratain MJ, Miller AA, McLeod HL, Venook AP, Egorin MJ, Schilsky RL. The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective. Clin Cancer Res. 2006 Jun 1; 12(11 Pt 2):3612s-6s.
        View in: PubMed
      82. Atencio IA, Grace M, Bordens R, Fritz M, Horowitz JA, Hutchins B, Indelicato S, Jacobs S, Kolz K, Maneval D, Musco ML, Shinoda J, Venook A, Wen S, Warren R. Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial. Cancer Gene Ther. 2006 Feb; 13(2):169-81.
        View in: PubMed
      83. Rajpal S, Venook AP. Targeted therapy in colorectal cancer. Clin Adv Hematol Oncol. 2006 Feb; 4(2):124-32.
        View in: PubMed
      84. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol. 2006 Jan 20; 24(3):379-85.
        View in: PubMed
      85. Venook AP, Blanke CD, Niedzwiecki D, Lenz HJ, Taylor JR, Hollis DR, Sutherland S, Goldberg RM. Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma. Clin Colorectal Cancer. 2005 Nov; 5(4):292-4.
        View in: PubMed
      86. Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer. 2005 Jul 25; 93(2):195-9.
        View in: PubMed
      87. Engstrom PF, Benson AB, Chen YJ, Choti MA, Dilawari RA, Enke CA, Fakih MG, Fuchs C, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW, Rao S, Saif MW, Saltz L, Skibber JM, Venook AP, Yeatman TJ. Rectal cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2005 Jul; 3(4):492-508.
        View in: PubMed
      88. Engstrom PF, Benson AB, Chen YJ, Choti MA, Dilawari RA, Enke CA, Fakih MG, Fuchs C, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW, Rao S, Saif MW, Saltz L, Skibber JM, Venook AP, Yeatman TJ. Anal canal cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2005 Jul; 3(4):510-5.
        View in: PubMed
      89. Engstrom PF, Benson AB, Chen YJ, Choti MA, Dilawari RA, Enke CA, Fakih MG, Fuchs C, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW, Rao S, Saif MW, Saltz L, Skibber JM, Venook AP, Yeatman TJ. Colon cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2005 Jul; 3(4):468-91.
        View in: PubMed
      90. Venook AP. Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma. Cancer. 2005 Jun 15; 103(12):2435-46.
        View in: PubMed
      91. Yao FY, Kinkhabwala M, LaBerge JM, Bass NM, Brown R, Kerlan R, Venook A, Ascher NL, Emond JC, Roberts JP. The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant. 2005 Apr; 5(4 Pt 1):795-804.
        View in: PubMed
      92. Venook A. Critical evaluation of current treatments in metastatic colorectal cancer. Oncologist. 2005 Apr; 10(4):250-61.
        View in: PubMed
      93. Mehta KR, Nakao K, Zuraek MB, Ruan DT, Bergsland EK, Venook AP, Moore DH, Tokuyasu TA, Jain AN, Warren RS, Terdiman JP, Waldman FM. Fractional genomic alteration detected by array-based comparative genomic hybridization independently predicts survival after hepatic resection for metastatic colorectal cancer. Clin Cancer Res. 2005 Mar 1; 11(5):1791-7.
        View in: PubMed
      94. Alberts DS, Muggia FM, Carmichael J, Winer EP, Jahanzeb M, Venook AP, Skubitz KM, Rivera E, Sparano JA, DiBella NJ, Stewart SJ, Kavanagh JJ, Gabizon AA. Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Semin Oncol. 2004 Dec; 31(6 Suppl 13):53-90.
        View in: PubMed
      95. Goldberg RM, Venook AP, Schilsky RL. Cetuximab in the treatment of colorectal cancer. Clin Adv Hematol Oncol. 2004 Nov; 2(11):1-10; quiz 11-12.
        View in: PubMed
      96. Whisenant J, Venook A. Regional therapy of liver metastases. Curr Treat Options Oncol. 2004 Oct; 5(5):427-37.
        View in: PubMed
      97. Venook AP. Key research issues in the management of hepatocellular carcinoma. Cancer Chemother Pharmacol. 2004 Sep; 54 Suppl 1:S87-90.
        View in: PubMed
      98. Venook AP. Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition. J Natl Compr Canc Netw. 2004 Sep; 2 Suppl 2:S74-84.
        View in: PubMed
      99. Whisenant J, Venook A. Defining the role of hepatic arterial infusion chemotherapy in metastatic colorectal cancer. Oncology (Williston Park). 2004 May; 18(6):762-8; discussion 769-73.
        View in: PubMed
      100. Allen J, Venook A. Hepatocellular carcinoma: epidemic and treatment. Curr Oncol Rep. 2004 May; 6(3):177-83.
        View in: PubMed
      101. Melisko ME, Fox R, Venook A. Reactivation of hepatitis C virus after chemotherapy for colon cancer. Clin Oncol (R Coll Radiol). 2004 May; 16(3):204-5.
        View in: PubMed
      102. Wilson MW, Kerlan RK, Fidelman NA, Venook AP, LaBerge JM, Koda J, Gordon RL. Hepatocellular carcinoma: regional therapy with a magnetic targeted carrier bound to doxorubicin in a dual MR imaging/ conventional angiography suite--initial experience with four patients. Radiology. 2004 Jan; 230(1):287-93.
        View in: PubMed
      103. Venook AP, Enders Klein C, Fleming G, Hollis D, Leichman CG, Hohl R, Byrd J, Budman D, Villalona M, Marshall J, Rosner GL, Ramirez J, Kastrissios H, Ratain MJ. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol. 2003 Dec; 14(12):1783-90.
        View in: PubMed
      104. Venook AP. Induction therapy in patients with metastatic colorectal cancer. Semin Oncol. 2003 Aug; 30(4 Suppl 12):25-9.
        View in: PubMed
      105. Venook AP. Colorectal metastases confined to the liver: a unique opportunity? Semin Oncol. 2003 Aug; 30(4 Suppl 15):34-9.
        View in: PubMed
      106. Visser BC, Venook AP, Patti MG. Adjuvant and neoadjuvant therapy for esophageal cancer: a critical reappraisal. Surg Oncol. 2003 Jul; 12(1):1-7.
        View in: PubMed
      107. Venook AP. Testing the water before diving off the cutting edge. Ann Surg Oncol. 2003 May; 10(4):332-3.
        View in: PubMed
      108. Bergsland EK, Venook AP. Shedding old paradigms: developing viruses to treat cancer. J Clin Oncol. 2002 May 1; 20(9):2220-2.
        View in: PubMed
      109. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001 Jun; 33(6):1394-403.
        View in: PubMed
      110. Venook AP, Warren RS. Therapeutic approaches to metastasis confined to the liver. Curr Oncol Rep. 2001 Mar; 3(2):109-15.
        View in: PubMed
      111. Mulvihill S, Warren R, Venook A, Adler A, Randlev B, Heise C, Kirn D. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Ther. 2001 Feb; 8(4):308-15.
        View in: PubMed
      112. Venook AP. Hepatocellular carcinoma. Curr Treat Options Oncol. 2000 Dec; 1(5):407-15.
        View in: PubMed
      113. Benson AB, Choti MA, Cohen AM, Doroshow JH, Fuchs C, Kiel K, Martin EW, McGinn C, Petrelli NJ, Posey JA, Skibber JM, Venook A, Yeatman TJ. NCCN Practice Guidelines for Colorectal Cancer. Oncology (Williston Park). 2000 Nov; 14(11A):203-12.
        View in: PubMed
      114. Bergsland EK, Venook AP. Hepatocellular carcinoma. Curr Opin Oncol. 2000 Jul; 12(4):357-61.
        View in: PubMed
      115. Venook AP, Egorin MJ, Rosner GL, Hollis D, Mani S, Hawkins M, Byrd J, Hohl R, Budman D, Meropol NJ, Ratain MJ. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol. 2000 Jul; 18(14):2780-7.
        View in: PubMed
      116. Venook AP, Althaus B, Warren RS. Hepatic arterial infusion of chemotherapy for metastatic colorectal cancer. N Engl J Med. 2000 May 18; 342(20):1524; author reply 1526-7.
        View in: PubMed
      117. Venook AP. Regional strategies for managing hepatocellular carcinoma. Oncology (Williston Park). 2000 Mar; 14(3):347-54; discussion 354, 359, 363-4.
        View in: PubMed
      118. Bloom AI, Gordon RL, Ahl KH, Kerlan RK, LaBerge JM, Wilson MW, Venook AP, Warren R. Transcatheter embolization for the treatment of misperfusion after hepatic artery chemoinfusion pump implantation. Ann Surg Oncol. 1999 Jun; 6(4):350-8.
        View in: PubMed
      119. Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, Saltz L, Dandona P, Anthony L. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999 Feb; 17(2):600-6.
        View in: PubMed
      120. Venook AP. Embolization and chemoembolization therapy for neuroendocrine tumors. Curr Opin Oncol. 1999 Jan; 11(1):38-41.
        View in: PubMed
      121. Floren LC, Hebert MF, Venook AP, Jordan VC, Cisneros A, Somberg KA. Tamoxifen in liver disease: potential exacerbation of hepatic dysfunction. Ann Oncol. 1998 Oct; 9(10):1123-6.
        View in: PubMed
      122. Venook AP, Egorin MJ, Rosner GL, Brown TD, Jahan TM, Batist G, Hohl R, Budman D, Ratain MJ, Kearns CM, Schilsky RL. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol. 1998 May; 16(5):1811-9.
        View in: PubMed
      123. Venook AP. Update on hepatic intra-arterial chemotherapy. Oncology (Williston Park). 1997 Jul; 11(7):947-57; discussion 961-2, 964, 970.
        View in: PubMed
      124. Venook AP. Can a vitamin prevent hepatocellular carcinoma? Hepatology. 1997 Jan; 25(1):249-50.
        View in: PubMed
      125. Dorsey BV, Benjamin LE, Rauscher F, Klencke B, Venook AP, Warren RS, Weidner N. Intra-abdominal desmoplastic small round-cell tumor: expansion of the pathologic profile. Mod Pathol. 1996 Jun; 9(6):703-9.
        View in: PubMed
      126. Venook A, Goodnight J, Kumar S, Taylor C, Gilden R, Figlin RA. Practice guidelines for colorectal cancer. Cancer J Sci Am. 1996 May-Jun; 2(3A Suppl):S23-36.
        View in: PubMed
      127. Goodnight J, Venook A, Ames M, Taylor C, Gilden R, Figlin RA. Practice guidelines for esophageal cancer. Cancer J Sci Am. 1996 May-Jun; 2(3A Suppl):S37-43.
        View in: PubMed
      128. Venook A, Goodnight J, Smith NG, Taylor C, Gilden R, Figlin RA. Practice guidelines for gastric cancer. Cancer J Sci Am. 1996 May-Jun; 2(3A Suppl):S45-52.
        View in: PubMed
      129. Goodnight J, Venook A, Fringer J, Taylor C, Gilden R, Figlin RA. Practice guidelines for pancreatic cancer. Cancer J Sci Am. 1996 May-Jun; 2(3A Suppl):S53-60.
        View in: PubMed
      130. Venook AP, Warren RS. Regional chemotherapy approaches for primary and metastatic liver tumors. Surg Oncol Clin N Am. 1996 Apr; 5(2):411-427.
        View in: PubMed
      131. Kirn D, Venook A, Pena I. Pulmonary aspergillosis masquerading as progressive post-transplant lymphoma. Transpl Int. 1996; 9(5):517-9.
        View in: PubMed
      132. Venook AP, Ferrell LD, Roberts JP, Emond J, Frye JW, Ring E, Ascher NL, Lake JR. Liver transplantation for hepatocellular carcinoma: results with preoperative chemoembolization. Liver Transpl Surg. 1995 Jul; 1(4):242-8.
        View in: PubMed
      133. Venook AP. Treatment of hepatocellular carcinoma: too many options? J Clin Oncol. 1994 Jun; 12(6):1323-34.
        View in: PubMed
      134. Small EJ, Venook AP, Damon LE. Gallium-avid thymic hyperplasia in an adult after chemotherapy for Hodgkin disease. Cancer. 1993 Aug 1; 72(3):905-8.
        View in: PubMed
      135. Venook AP. Liver transplantation for hepatocellular carcinoma. Hepatology. 1993 Jul; 18(1):218-9.
        View in: PubMed
      136. Wilkinson MJ, Frye JW, Small EJ, Venook AP, Carroll PR, Ernest ML, Stagg RJ. A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma. Cancer. 1993 Jun 1; 71(11):3601-4.
        View in: PubMed
      137. Park JW, Mehrotra B, Barnett BO, Baron AD, Venook AP. The Sweet syndrome during therapy with granulocyte colony-stimulating factor. Ann Intern Med. 1992 Jun 15; 116(12 Pt 1):996-8.
        View in: PubMed
      138. Meyerhoff DJ, Karczmar GS, Valone F, Venook A, Matson GB, Weiner MW. Hepatic cancers and their response to chemoembolization therapy. Quantitative image-guided 31P magnetic resonance spectroscopy. Invest Radiol. 1992 Jun; 27(6):456-64.
        View in: PubMed
      139. Frye JW, Venook AP, Ostroff JW, Mulvihill SJ, Warren RS, Pellegrini CA, Ring EJ, Stagg RJ. Hepatic intra-arterial methylene blue injection during endoscopy: a method of detecting gastroduodenal misperfusion in patients receiving hepatic intra-arterial chemotherapy via an implanted pump. Gastrointest Endosc. 1992 Jan-Feb; 38(1):52-4.
        View in: PubMed
      140. Stagg RJ, Venook AP, Chase JL, Lewis BJ, Warren RS, Roh M, Mulvihill SJ, Grobman BJ, Rayner AA, Hohn DC. Alternating hepatic intra-arterial floxuridine and fluorouracil: a less toxic regimen for treatment of liver metastases from colorectal cancer. J Natl Cancer Inst. 1991 Mar 20; 83(6):423-8.
        View in: PubMed
      141. Venook AP, Stagg RJ, Lewis BJ, Chase JL, Ring EJ, Maroney TP, Hohn DC. Chemoembolization for hepatocellular carcinoma. J Clin Oncol. 1990 Jun; 8(6):1108-14.
        View in: PubMed
      142. Venook AP, Davenport Y, Tseng A. Activity of coumarin and cimetidine in metastatic renal cell carcinoma. J Clin Oncol. 1989 Mar; 7(3):402-3.
        View in: PubMed
      143. DeGregorio MW, Wiebe VJ, Venook AP, Holleran WM. Elevated plasma tamoxifen levels in a patient with liver obstruction. Cancer Chemother Pharmacol. 1989; 23(3):194-5.
        View in: PubMed
      144. Venook AP, Stagg RJ, Lewis BJ. Regional chemotherapy for colorectal cancer metastatic to the liver. Oncology (Williston Park). 1988 Mar; 2(3):19-26.
        View in: PubMed
      145. Mass RD, Venook AP, Linker CA, Zipkin RE. Pentoxifylline and aplastic anemia. Ann Intern Med. 1987 Sep; 107(3):427-8.
        View in: PubMed
      146. Venook AP, Shuman MA, Corash L. Prophylactic heparin in APL. Blood. 1987 Sep; 70(3):886-7.
        View in: PubMed
      147. Venook AP, Tseng A, Meyers FJ, Silverberg I, Boles R, Fu KK, Jacobs CD. Cisplatin, doxorubicin, and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group. J Clin Oncol. 1987 Jun; 5(6):951-5.
        View in: PubMed
      148. White RH, Hong R, Venook AP, Daschbach MM, Murray W, Mungall DR, Coleman RW. Initiation of warfarin therapy: comparison of physician dosing with computer-assisted dosing. J Gen Intern Med. 1987 May-Jun; 2(3):141-8.
        View in: PubMed
      Alan's Networks
      Click the "See All" links for more information and interactive visualizations!
      Related Concepts
      Derived automatically from this person's publications.
      _
      Co-Authors
      People in Profiles who have published with this person.
      _
      Related Authors
      People who share related concepts with this person.
      _
      Same Department
      Back to TOP